A5063441489- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Cancer therapeutics and mechanisms
- Cancer Treatment and Pharmacology
- CAR-T cell therapy research
- Neuroendocrine Tumor Research Advances
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Treatments and Studies
- Cancer Cells and Metastasis
- Radiomics and Machine Learning in Medical Imaging
- Cancer-related Molecular Pathways
- Immunotherapy and Immune Responses
- Inflammatory mediators and NSAID effects
- Brain Metastases and Treatment
- Economic and Financial Impacts of Cancer
- Peptidase Inhibition and Analysis
- Multiple and Secondary Primary Cancers
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Global Cancer Incidence and Screening
- Advanced Breast Cancer Therapies
- Fibroblast Growth Factor Research
Fox Chase Cancer Center
2009-2025
Case Comprehensive Cancer Center
2020-2024
Research for Equity And Community Health Trust
2024
Realistic Education in Action Coalition to Foster Health
2024
University of Maryland, Baltimore
2011-2023
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
2009-2023
Temple University Health System
2023
Huisarts en Wetenschap
2021
University Medical Center Utrecht
2021
University of Maryland Medical Center
2004-2020
The National Lung Screening Trial (NLST) is a randomized multicenter study comparing low-dose helical computed tomography (CT) with chest radiography in the screening of older current and former heavy smokers for early detection lung cancer, which leading cause cancer-related death United States. Five-year survival rates approach 70% surgical resection stage IA disease; however, more than 75% individuals have incurable locally advanced or metastatic disease, latter having 5-year less 5%. It...
After patients have undergone colonoscopic polypectomy, it is uncertain whether examination or a barium enema the better method of surveillance.
Ideas and Opinions27 March 2020A War on Two Fronts: Cancer Care in the Time of COVID-19FREEAlexander Kutikov, MD, David S. Weinberg, MSc, Martin J. Edelman, Eric M. Horwitz, Robert G. Uzzo, MBA, Richard I. Fisher, MDAlexander MDFox Chase Center, Philadelphia, Pennsylvania (A.K., D.S.W., M.J.E., E.M.H., R.G.U., R.I.F.)Search for more papers by this author, MScFox MBAFox authorAuthor, Article, Disclosure Informationhttps://doi.org/10.7326/M20-1133 SectionsAboutVisual AbstractPDF ToolsAdd to...
Survival of patients with completely resected non-small-cell lung cancer (NSCLC) is unsatisfactory, and in 2002, the benefit adjuvant chemotherapy was not established. This phase III study assessed impact postoperative gefitinib on overall survival (OS).Patients (stage IB, II, or IIIA) NSCLC stratified by stage, histology, sex, radiotherapy, were randomly assigned (1:1) to receive 250 mg per day placebo for 2 years. Study end points OS, disease-free (DFS), toxicity.As a result early closure,...
<h3>Importance</h3> Stereotactic body radiation therapy (SBRT) has become a standard treatment for patients with medically inoperable early-stage lung cancer. However, its effectiveness in suitable surgery is unclear. <h3>Objective</h3> To evaluate whether noninvasive SBRT delivered on an outpatient basis can safely eradicate cancer and cure selected operable cancer, obviating the need surgical resection. <h3>Design, Setting, Participants</h3> Single-arm phase 2 NRG Oncology Radiation...
Purpose The phase III OAM4971g study (METLung) examined the efficacy and safety of onartuzumab plus erlotinib in patients with locally advanced or metastatic non–small-cell lung cancer selected by MET immunohistochemistry whose disease had progressed after treatment a platinum-based chemotherapy regimen. Patients Methods were randomly assigned at one-to-one ratio to receive (15 mg/kg intravenously on day 1 each 21-day cycle) daily oral 150 mg intravenous placebo mg. primary end point was...
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management patients with SCLC, including diagnosis, primary treatment, surveillance relapse, and subsequent treatment. This selection the journal focuses on metastatic (known as extensive-stage) which is more common than limited-stage SCLC. Systemic therapy alone can palliate symptoms prolong survival most extensive-stage disease. Smoking cessation counseling intervention...
Platinum-doublet chemotherapy regimens have been shown to extend survival in fit patients with advanced non-small-cell lung cancer (AdvNSCLC). This study extends recent population-based analyses focusing on treatment and benefit from use of platinum-doublet therapy, addressing the role performance status (PS).Patients >or= 66 years AdvNSCLC incident 1997 2002 were identified SEER-Medicare. Multivariate models examined tumor patient characteristics associated receipt any compared single-agent...
Erlotinib is clinically effective in patients with non-small-cell lung cancer (NSCLC) who have adenocarcinoma, are never or limited former smokers, EGFR mutant tumors. We investigated the efficacy of erlotinib alone combination chemotherapy these characteristics.
We sought to characterize the pharmacokinetics (PK) and determine a tolerable dose of oral sorafenib in patients with hepatic or renal dysfunction.Patients were assigned one nine cohorts: cohort 1, bilirubin < = upper limit normal (ULN) AST ULN creatinine clearance (CC) > 60 mL/min; 2, more than but 1.5x and/or ULN; 3, CC between 40 59 4, 3x (any AST); 5, 20 39 6, 10x 7, less 8, albumin 2.5 mg/dL bilirubin/AST); 9, hemodialysis. Sorafenib was administered as 400-mg on day 1 for PK,...
Increased expression of eicosanoids in cancer has been associated with adverse prognosis. We performed a randomized phase II trial to test the hypothesis that inhibitors two eicosanoid pathways (cyclooxygenase-2 [COX-2], celecoxib and 5-lipoxygenase [5-LOX], zileuton) added chemotherapy would improve outcome advanced non-small-cell lung (NSCLC).Patients NSCLC, performance status 0 2, no prior therapy were eligible. All patients received carboplatin area under curve (AUC) 5.5 mg/mL x min day...
The regimens of carboplatin plus paclitaxel (CP) and methotrexate, vinblastine, doxorubicin, cisplatin (M-VAC) were compared in patients with advanced urothelial carcinoma.Patients metastatic carcinoma randomized to receive either CP (paclitaxel at a dose 225 mg/m(2) [targeted area under the concentration-time curve (AUC) 6] given every 21 days) or standard M-VAC dosage.Eighty-five respective treatment (41 44 M-VAC). Response rates overall survival similar for both arms. Patients treated had...
Tumor shrinkage categorized as complete response (CR) or partial (PR) is a fundamental efficacy measure for new cancer treatments and often considered surrogate overall survival. However, any given treatment, many more patients typically achieve stable disease (SD) have progressive (PD) than response. We hypothesized that PD (or its converse, control rate [DCR], consisting of CR, PR, SD) stronger predictor survival alone in advanced non-small-cell lung (NSCLC), this determination might be...
8000 Background: A placebo-controlled, phase II trial of erlotinib + onartuzumab, a humanized monovalent antibody to the MET receptor, demonstrated benefit in progression-free survival (PFS) when compared with patients MET-positive NSCLC (JCO 2013;31;4105). The aim METLung was confirm efficacy and safety onartuzumab NSCLC. Methods: This prospective, randomized, double-blind, placebo-controlled enrolled previously treated stage IIIb/IV diagnostic status determined by an immunohistochemistry...
Abstract Purpose Taxanes are a cornerstone treatment in early and advanced stage breast cancer other common solid tumor malignancies; however, the development of chemotherapy induced peripheral neuropathy (CIPN) often necessitates dose-reduction, which may hamper effectiveness drug compromise survival outcomes especially when used adjuvant setting. Limited literature is available on prevalence severity dose reduction due to CIPN. We sought determine frequency CIPN-induced patients who...
PIWI-interacting RNAs (piRNAs) are thought to silence transposon and gene expression during development. However, the roles of piRNAs in somatic tissues largely unknown. Here we report identification 555 human lung bronchial epithelial (HBE) non-small cell cancer (NSCLC) lines, including 295 that do not exist databases termed as piRNA-like sncRNAs or piRNA-Ls. Distinctive piRNA/piRNA-L patterns observed between HBE NSCLC cells. piRNA-like-163 (piR-L-163), top downregulated piRNA-L cells,...